

Volition launches Nu.Q Vet Cancer test in Asia

26 April 2022 | News

The firm launched the test through its appointed distributor SAGE Healthcare

VolitionRx, a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of cancers and other life-altering diseases in both humans and animals, has announced the launch of its Nu.Q Vet Cancer Test in Asia through its appointed distributor SAGE Healthcare Private Limited.

As previously announced, SAGE was appointed in December 2021 to serve as a non-exclusive licensee and distributor for Volition's Nu.Q® Vet Cancer Test in centralized labs in Singapore. Following pre-launch preparations, SAGE hosted a launch event featuring Professor Heather Wilson-Robles, Chief Medical Officer, Volition Veterinary, and Dr. Tom Butera, Chief Executive Officer, Volition Veterinary. SAGE is now actively marketing the Test and will be processing samples and providing test results from its centralized lab with immediate effect.

Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals